The Lower Drug Costs Through Competition Act would give the FDA six months to approve generic drugs, for which a brand name version of the active drug has already been authorized. The bill has bipartisan support, and he believes it could be passed as part of the year-end negotiations in President Obama’s lame-duck session.
By:
Chris Gray
U.S. Rep. Kurt Schrader has introduced legislation with bipartisan support that he believes will limit pharmaceutical profiteering and encourage manufacturers to produce generic versions of drugs for which there’s currently no competition.
